- Home
- / SGD Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
SGD Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and acquistions and subsidiaries.
Revenue
€178.6 M
FY, 2021
CreditSafe Score
?
Score changed on Jul 03, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|
| Revenue | 204.8M | 209.1M | 178.6M |
| Cost of goods sold | 49.1M | 47.4M | 43.9M |
| Gross profit | 155.7M | 161.7M | 134.7M |
| Gross profit margin, % | 76.0% | 77.3% | 75.4% |
| General and administrative expense | 51.3M | 53.4M | 52.5M |
| Operating expense total | 150.3M | 153.6M | 161.7M |
| EBIT | 19.0M | 17.4M | (8.9M) |
| EBIT margin, % | 9.3% | 8.3% | -5.0% |
| Investment income | 465.8K | 1.1M | |
| Interest income | 29.4K | 8.6K | 9.3K |
| Interest expense | 2.8M | 2.7M | 2.7M |
| Pre tax profit | 14.5M | 14.1M | 165.6K |
| Net Income | 8.6M | 10.5M | (1.3M) |
Acquisitions & Subsidiaries
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content only available in Craft’s Intelligence Portal View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |